HOW TO USE GRASEBY SYRINGE DRIVER

Medsafe also recognises the on-going risks associated with these devices and therefore advises users to give immediate consideration to sourcing alternative equipment which meets the “Essential Principles” for safety and efficacy. Medsafe has commenced consultation with healthcare professionals and stakeholder groups to determine a process and timeline for the removal of all existing Graseby MS-series devices from clinical use. Medsafe recognises the clinical implications of this situation and thus does not currently require existing devices to be recalled or withdrawn from clinical use when alternates are not available provided the manufacturer’s instructions are carefully observed. These syringe drivers are commonly used in palliative care and other situations to provide continuous ambulatory infusion of medicines. Although available for some time it has become apparent that the safety features of the Graseby MS-Series devices have not been upgraded to comply with current minimum standards as recommended by internationally respected regulators.

Spare parts and service for existing devices continue to be available through Smiths Medical at this time. These guidelines reflect international minimum grraseby for the safety and effectiveness of medical devices.

This document briefs you on the situation, the reasons for Medsafe’s action and the action that will need to be taken by users of these devices.

Medsafe recognises the clinical implications of this situation and thus does not currently require existing devices to be recalled or withdrawn from clinical use when alternates are not available provided the manufacturer’s instructions are carefully observed.

Although available for some time it has become apparent that the safety features of the Graseby MS-Series devices have not been upgraded to comply with current minimum standards as recommended by graseny respected regulators.

Medsafe: New Zealand Medicines and Medical Devices Safety Authority

Regulators in several countries, including Australia and the UK, have previously issued safety alerts in relation to the Graseby MS-Series Syrinbe Driver and these have related to possibilities of over-infusion, tampering with the device and yow between the different models of Graseby device.

However Medsafe can assist users by providing information about the notification status of alternative devices on the Web Assisted Notification of Devices WAND database and by facilitating end-user group discussions.

Users should consider how best to phase the use of these devices out and consider which device or devices may be used as a satisfactory replacement.

Medsafe also recognises the on-going risks associated with these devices and therefore advises grasehy to give immediate consideration to sourcing alternative equipment which meets the “Essential Principles” for safety and efficacy.

These syringe drivers are commonly used in palliative care and other situations to provide continuous ambulatory infusion of medicines. Medsafe has commenced consultation with healthcare professionals and stakeholder groups to determine a process and timeline for the removal of all existing Graseby MS-series devices from clinical use.

Medsafe does not undertake comparative evaluation of medical devices, nor is it appropriate for Medsafe to endorse any specific device.